Biophytis: Convening of a second Combined General Meeting at a later date

Paris, France, Cambridge (Massachusetts, United States), June 3, 2022 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging and to improve the functional results of patients suffering from age-related illnesses, informs its shareholders that the Combined Annual General Meeting of June 3, 20022 was unable to deliberate, as the quorum was not reached.

The shareholders taking part in the vote together held 23,514,980 shares, or 15.45% of the capital and 16.19% of the voting rights. The quorum necessary to hold an ordinary general meeting on first call of 20% is not reached and the quorum necessary to hold an extraordinary general meeting on first call of 25% is not reached.

Consequently, in the absence of a quorum required to rule on the ordinary and extraordinary resolutions, none of the proposed resolutions was put to the vote of the shareholders and the general meeting was adjourned. The shareholders will thus be invited to a combined general meeting on second call which will be held at a later date and will relate to the same agenda.

The vote of shareholders who voted by post or by Internet at the first general meeting remains valid and counted for the General Meeting on second call.

* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional outcomes of patients suffering from age-related diseases, including respiratory failure in patients with COVID-19. Sarconeos (BIO101), our lead drug candidate, is an orally administered small molecule that has completed its Phase 2 clinical study in the US and Europe (SARA-INT) in the treatment of sarcopenia. It is also being studied in a two-part Phase 2/3 (COVA) clinical study for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America and the United States. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne muscular dystrophy.
The company is based in Paris, France, and Cambridge, Massachusetts in the United States. The company’s ordinary shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825) (Ticker: ALBPS -ISIN: FR0012816825), and the ADSs are listed on the Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040 ).
For more information : www.biophytis.com

Warning
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook”, “believe”, “expect”, “potential”, “continue”, “may”, “will”, “should”. “, “could”, “seek”, “predict”, “intend”, “trend”, “plan”, “estimate”, “anticipate” or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis’ anticipated timing for its Part 1 interim analysis and the release of full study results. These forward-looking statements are based on assumptions that Biophytis believes are reasonable. However, there is no guarantee that the statements contained in these forward-looking statements will be verified, which are subject to various risks and uncertainties, including delays in recruitment or retention of patients, interruptions in the supply or chain of supply, the ability of Biophytis to obtain the necessary regulatory approvals, delays related to COVID-19 and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or considered insignificant by Biophytis. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements. Please also refer to the “Risks and Uncertainties Facing the Company” section of the Company’s 2021 Annual Report and the “Risk Factors” section of Form 20-F and other forms to be filed respectively with the AMF and the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contact Biophytis for Investor Relations
Philippe Rousseau, CFO
[email protected]

Media contacts
Antoine Dennis: [email protected] – +33 6 18 07 83 27
Agatha Boggio: [email protected] – +33 7 62 77 69 42